NIH-AACR Cancer, Autoimmunity, and Immunology Conference
See the Program PDF Here
NOTICE OF Change To Virtual meeting
Last updated March 10, 2020
The AACR is closely monitoring the continuing developments pertaining to the novel coronavirus. The safety and security of AACR conference attendees are our top priorities. After careful evaluation of currently available information, and a thorough consideration of all the factors essential to conduct a meeting, the AACR together with NIH leadership has determined that it is in the best interest of all concerned that the NIH-AACR Cancer, Autoimmunity, and Immunology Conference scheduled for March 23-24, in Bethesda, Maryland, be held as an entirely virtual conference.
The information reviewed included the U.S. Federal government’s enforcement of travel prohibitions and restrictions on international travelers to enter the U.S., and the imposition of travel restrictions issued by cancer centers, academic institutions, government agencies, and pharmaceutical companies.
Please note that this decision applies only to the NIH-AACR Cancer, Autoimmunity, and Immunology Conference.
We recognize that the new data, exchange of information, and opportunities for collaboration offered by this conference are highly valued by the cancer research community, and we believe that holding the conference virtually will support these goals. Presentations and panel discussions will take place via WebEx on March 23-24, 2020, as previously scheduled.
Webcast login information will be sent to registrants by email soon. Please note the following information:
- Registration for the webcast is free and will remain open through March 16.
- Individuals who previously registered to attend the meeting in-person will be automatically registered for the webcast.
- Registrants who have a room reservation should contact their hotel directly to cancel.
- Many airlines have adjusted their rebooking and cancellation policies in response to the novel coronavirus situation. Registrants who already booked travel should contact their airlines or booking agents directly to cancel their travel to Bethesda.
- Abstract submission closes on March 16. There will not be any opportunities to present ePosters or short talks. Authors of accepted abstracts may choose to have their abstracts posted online as part of the digital program; authors will be contacted soon with additional information.
- The NIH-AACR Cancer, Autoimmunity, and Immunology Conference is a Continuing Medical Education Activity and AMA PRA Category 1 Credits™ will be available. If you are a physician, this activity can help you can meet your Maintenance of Certification (MOC) point requirements. The meeting is CME/MOC accredited.
- For additional questions, please contact Elizabeth Barksdale at [email protected].
Julie R. Brahmer, Director, Thoracic Oncology Program and Upper Aerodigestive Clinical Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Elad Sharon, Senior Investigator, National Cancer Institute, Bethesda, Maryland
Connie Sommers, Program Director, National Cancer Institute, Bethesda, Maryland
Howard Young, Senior Investigator, National Cancer Institute, Bethesda, Maryland
Ravi Madan, Clinical Director, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Katarzyna (Kasia) Bourcier, Program Officer, National Cancer Institute, Bethesda, Maryland
Marie Mancini, Program Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland
Annette Rothermel, Section Chief, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Lisa Spain, Program Director, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
Held for the first time in 2018, the Cancer, Autoimmunity, and Immunology Conference was created to delve into 1) understanding the biology of immune-related, adverse events that have occurred in cancer patients treated with immunotherapies and how that might inform the study of autoimmune disease; and 2) defining the potential for the study of autoimmune-disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies.
Professional Educational Grant
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available